| abstract |
The application refers to biomarkers for diagnosing allograft rejection, in particular, when the underlying cause is antibody-mediated rejection. The application also refers to an in vitro method for diagnosing allograft rejection in a patient, the method comprising determining in an isolated sample from the patient the level of expression of SIGLEC17P and/or of at least one of its associated downstream coding genes selected from the group consisting of AP4S1, ZMYM6, USP21, DMAP1, SUPT5H, TP53BP1, NECAB3, BTD, DACT1, and combinations thereof, wherein when the level of expression of SIGLEC17P and/or of at least one of its associated downstream coding genes is higher than a reference value, this is indicative of allograft rejection. |